Liminatus Pharma Stock Price, News & Analysis
Company Description
Liminatus Pharma (NASDAQ: LIMNW) is a publicly traded company in the Biological Products, (no Diagnostic Substances) sector.
LIMNW stock has declined 63.7% over the past year. Shares last traded at $0.0400.
This page provides a comprehensive overview of LIMNW stock, including real-time price data, latest news, SEC filings, insider trading activity, financial highlights, upcoming events, and short interest trends.
Stock Performance
Liminatus Pharma (LIMNW) stock last traded at $0.0400. Over the past 12 months, the stock has lost 63.7%.
Latest News
SEC Filings
Liminatus Pharma has filed 5 recent SEC filings, including 2 Form 8-K, 1 Form 10-K, 1 Form SCHEDULE 13G, 1 Form S-1. The most recent filing was submitted on March 31, 2026. SEC filings provide transparency into a company's financial condition, material events, and regulatory compliance. View all LIMNW SEC filings →
Financial Highlights
Upcoming Events
Short Interest History
Short interest in Liminatus Pharma (LIMNW) currently stands at 1.1 thousand shares, up 342.3% from the previous reporting period, representing 0.0% of the float. Over the past 12 months, short interest has decreased by 73.9%. This relatively low short interest suggests limited bearish sentiment.
Days to Cover History
Days to cover for Liminatus Pharma (LIMNW) currently stands at 1.0 days. This low days-to-cover ratio indicates high liquidity, allowing short sellers to quickly exit positions if needed. The ratio has shown significant volatility over the period, ranging from 1.0 to 1.6 days.
LIMNW Company Profile & Sector Positioning
Liminatus Pharma (LIMNW) operates in the Biological Products, (no Diagnostic Substances) sector and is listed on the NASDAQ.